Jarkko P Hytönen, Olli Leppänen, Jouni Taavitsainen, Petra Korpisalo, Svetlana Laidinen, Kari Alitalo, Jonas Wadström, Tuomas T Rissanen, Seppo Ylä-Herttuala
{"title":"通过生长因子治疗改善小直径ePTFE血管移植的内皮化。","authors":"Jarkko P Hytönen, Olli Leppänen, Jouni Taavitsainen, Petra Korpisalo, Svetlana Laidinen, Kari Alitalo, Jonas Wadström, Tuomas T Rissanen, Seppo Ylä-Herttuala","doi":"10.1530/VB-18-0001","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prosthetic vascular grafts in humans characteristically lack confluent endothelialization regardless of the duration of implantation. Use of high-porosity grafts has been proposed as a way to induce endothelialization through transgraft capillarization, although early experiments failed to show increased healing in man.</p><p><strong>Objectives: </strong>We hypothesized that transduction of tissues around the prosthetic conduit with vectors encoding VEGF receptor-2 (VEGFR2) ligands would augment transinterstitial capillarization and induce luminal endothelialization of high-porosity ePTFE grafts.</p><p><strong>Methods: </strong>Fifty-two NZW rabbits received 87 ePTFE uni- or bilateral end-to-end interposition grafts in carotid arteries. Rabbits were randomized to local therapy with adenoviruses encoding AdVEGF-A165, AdVEGF-A109 or control AdLacZ and analyzed at 6 and 28 days after surgery by contrast-enhanced ultrasound and histology.</p><p><strong>Results: </strong>AdVEGF-A165 and AdVEGF-A109 dramatically increased perfusion in perigraft tissues at 6 days (14.2 ± 3.6 or 16.7 ± 2.6-fold increases, <i>P</i> < 0.05 and <i>P</i> < 0.01). At 28 days, the effect was no longer significantly higher than baseline. At 6 days, no luminal endothelialization was observed in any of the groups. At 28 days, AdVEGF-A109- and AdVEGF-A165-treated animals showed enhanced ingrowth of transinterstitial capillaries (66.0 ± 13.7% and 77.4 ± 15.7% of graft thickness vs 44.7 ± 24.4% in controls, <i>P</i> < 0.05) and improved luminal endothelialization (11.2 ± 26.3% and 11.4 ± 22.2%, AdVEGF-A109 and AdVEGF-A165 vs 0% in controls, <i>P</i> < 0.05). No increased stenosis was observed in the treatment groups as compared to LacZ controls.</p><p><strong>Conclusions: </strong>This study suggests that transient local overexpression of VEGFR2 ligands in the peri-implant tissues at the time of graft implantation is a novel strategy to increase endothelialization of high-porosity ePTFE vascular grafts and improve the patency of small-diameter vascular prostheses.</p>","PeriodicalId":75294,"journal":{"name":"Vascular biology (Bristol, England)","volume":"1 1","pages":"1-9"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/82/ad/VB-18-0001.PMC7449264.pdf","citationCount":"10","resultStr":"{\"title\":\"Improved endothelialization of small-diameter ePTFE vascular grafts through growth factor therapy.\",\"authors\":\"Jarkko P Hytönen, Olli Leppänen, Jouni Taavitsainen, Petra Korpisalo, Svetlana Laidinen, Kari Alitalo, Jonas Wadström, Tuomas T Rissanen, Seppo Ylä-Herttuala\",\"doi\":\"10.1530/VB-18-0001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Prosthetic vascular grafts in humans characteristically lack confluent endothelialization regardless of the duration of implantation. Use of high-porosity grafts has been proposed as a way to induce endothelialization through transgraft capillarization, although early experiments failed to show increased healing in man.</p><p><strong>Objectives: </strong>We hypothesized that transduction of tissues around the prosthetic conduit with vectors encoding VEGF receptor-2 (VEGFR2) ligands would augment transinterstitial capillarization and induce luminal endothelialization of high-porosity ePTFE grafts.</p><p><strong>Methods: </strong>Fifty-two NZW rabbits received 87 ePTFE uni- or bilateral end-to-end interposition grafts in carotid arteries. Rabbits were randomized to local therapy with adenoviruses encoding AdVEGF-A165, AdVEGF-A109 or control AdLacZ and analyzed at 6 and 28 days after surgery by contrast-enhanced ultrasound and histology.</p><p><strong>Results: </strong>AdVEGF-A165 and AdVEGF-A109 dramatically increased perfusion in perigraft tissues at 6 days (14.2 ± 3.6 or 16.7 ± 2.6-fold increases, <i>P</i> < 0.05 and <i>P</i> < 0.01). At 28 days, the effect was no longer significantly higher than baseline. At 6 days, no luminal endothelialization was observed in any of the groups. At 28 days, AdVEGF-A109- and AdVEGF-A165-treated animals showed enhanced ingrowth of transinterstitial capillaries (66.0 ± 13.7% and 77.4 ± 15.7% of graft thickness vs 44.7 ± 24.4% in controls, <i>P</i> < 0.05) and improved luminal endothelialization (11.2 ± 26.3% and 11.4 ± 22.2%, AdVEGF-A109 and AdVEGF-A165 vs 0% in controls, <i>P</i> < 0.05). No increased stenosis was observed in the treatment groups as compared to LacZ controls.</p><p><strong>Conclusions: </strong>This study suggests that transient local overexpression of VEGFR2 ligands in the peri-implant tissues at the time of graft implantation is a novel strategy to increase endothelialization of high-porosity ePTFE vascular grafts and improve the patency of small-diameter vascular prostheses.</p>\",\"PeriodicalId\":75294,\"journal\":{\"name\":\"Vascular biology (Bristol, England)\",\"volume\":\"1 1\",\"pages\":\"1-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/82/ad/VB-18-0001.PMC7449264.pdf\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vascular biology (Bristol, England)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1530/VB-18-0001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular biology (Bristol, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1530/VB-18-0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10
摘要
背景:无论植入时间长短,人类人工血管移植物的特点是缺乏融合内皮化。使用高孔隙度的移植物被认为是通过移植毛细血管诱导内皮化的一种方法,尽管早期的实验未能显示在人类中增加愈合。目的:我们假设用编码VEGF受体-2 (VEGFR2)配体的载体转导假体导管周围的组织会增加跨间质毛细血管化,并诱导高孔隙度ePTFE移植物的腔内内皮化。方法:52只NZW兔在颈动脉内置入ePTFE单侧或双侧端到端移植物87枚。兔随机接受编码AdVEGF-A165、AdVEGF-A109或对照AdLacZ的腺病毒局部治疗,并于术后6天和28天通过超声造影和组织学分析。结果:AdVEGF-A165和AdVEGF-A109在植入6天后显著增加了种植周组织的灌注(14.2±3.6或16.7±2.6倍)P P P P P P P结论:本研究提示,在植入时种植周组织中短暂的局部过表达VEGFR2配体是增加高孔隙度ePTFE血管移植物内皮化和改善小直径血管假体开放的一种新策略。
Improved endothelialization of small-diameter ePTFE vascular grafts through growth factor therapy.
Background: Prosthetic vascular grafts in humans characteristically lack confluent endothelialization regardless of the duration of implantation. Use of high-porosity grafts has been proposed as a way to induce endothelialization through transgraft capillarization, although early experiments failed to show increased healing in man.
Objectives: We hypothesized that transduction of tissues around the prosthetic conduit with vectors encoding VEGF receptor-2 (VEGFR2) ligands would augment transinterstitial capillarization and induce luminal endothelialization of high-porosity ePTFE grafts.
Methods: Fifty-two NZW rabbits received 87 ePTFE uni- or bilateral end-to-end interposition grafts in carotid arteries. Rabbits were randomized to local therapy with adenoviruses encoding AdVEGF-A165, AdVEGF-A109 or control AdLacZ and analyzed at 6 and 28 days after surgery by contrast-enhanced ultrasound and histology.
Results: AdVEGF-A165 and AdVEGF-A109 dramatically increased perfusion in perigraft tissues at 6 days (14.2 ± 3.6 or 16.7 ± 2.6-fold increases, P < 0.05 and P < 0.01). At 28 days, the effect was no longer significantly higher than baseline. At 6 days, no luminal endothelialization was observed in any of the groups. At 28 days, AdVEGF-A109- and AdVEGF-A165-treated animals showed enhanced ingrowth of transinterstitial capillaries (66.0 ± 13.7% and 77.4 ± 15.7% of graft thickness vs 44.7 ± 24.4% in controls, P < 0.05) and improved luminal endothelialization (11.2 ± 26.3% and 11.4 ± 22.2%, AdVEGF-A109 and AdVEGF-A165 vs 0% in controls, P < 0.05). No increased stenosis was observed in the treatment groups as compared to LacZ controls.
Conclusions: This study suggests that transient local overexpression of VEGFR2 ligands in the peri-implant tissues at the time of graft implantation is a novel strategy to increase endothelialization of high-porosity ePTFE vascular grafts and improve the patency of small-diameter vascular prostheses.